Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals

AIDS

Volumn 12, Issue 13, 1998, Pages 1625-1630

  Kaufmann, Gilbert R ^a   Duncombe, Chris ^b   Cunningham, Philip ^a   Beveridge, Alexander ^c   Carr, Andrew ^a   Sayer, David ^e   French, Martyn ^e   Cooper, David A ^a,d  

^a ST VINCENT S HOSPITAL   (Australia)

^b Holdsworth House General Practice   (Australia)

^c Grosvenor Street Clinic ^*  (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Antiviral therapy; HIV; Protease inhibitor; Ritonavir; Saquinavir

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DRUG TOLERANCE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; RASH; SIDE EFFECT; T LYMPHOCYTE; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4-CD8 RATIO; COHORT STUDIES; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; OBSERVATION; RISK FACTORS; RITONAVIR; SAQUINAVIR; TREATMENT FAILURE; VIRAL LOAD; ZIDOVUDINE;

EID: 0032505088     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199813000-00009     Document Type: Article

References (21)

1. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996, 334:1011-1017.
2. Gulick R, Mellors J, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
3. Hammer SM, Squirres KL, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
4. Jacobsen H, Haenggi M, Ott M, et al.: In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics and frequencies. J Infect Dis 1996, 173:1379-1387.
5. Lorenzi P, Yerli S, Abderrakim K, et al.: Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. AIDS 1997, 11:F95-F99.
6. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir Nature Med 1996, 2:760-766.
7. Schmidt JC, Ruiz L, Clotel B, et al.: Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996, 10:993-999.
8. Roberts NA: Drug-resistance patterns of saquinavir and other HIV protease inhibitors. AIDS 1995, 9 (Suppl 2):S27-S32.
9. Eberle J, Bechowsky B, Rose D, et al.: Resistance of HIV type 1 to protease inhibitor Ro 31-8959. AIDS Hum Retrovir 1995, 11:671-676.
10. Boucher C: Rational approaches to resistance: using saquinavir. AIDS 1996, 10 (Suppl 1):S13-S19.
11. Condra JH, Holder DJ, Schleif WA, et al.: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996, 70:8270-8276.
12. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
13. Tisdale M, Myers RE, Maschera B, et al.: Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agent Chemother 1995, 39:1704-1710.
14. Merry C, Barry MG, Mulcahy F, et al.: Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11:F29-F33.
15. Center for Disease Control (CDC), Atlanta (USA): Guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency infection. MMWR 1992, 1 (No. RR-8):1-17.
16. Markowitz M, Saag M, Powderly WG, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539.
17. Danner SDA, Carr A, Leonard JM, et al.: A short-term study of safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333;1528-1533.
18. Merry C, Barry M, Gibbons S, Mulcahy F, Back D: Improved tolerability of ritonavir derived from pharmacokinetic principles. Br J Clin Pharmacol 1996, 42:787.
19. Viraben R, Aquilina C: Indinavir-associated lipodystrophy. AIDS 1998, 12:137-139.
20. Lipsky JJ: Abnormal fat accumulation in patients with HIV-1 infection. Lancet 1998, 351:847-848.
21. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M: Buffalo hump in men with HIV-1 infection. Lancet 1998, 351:867-870.